High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Last updated: April 9, 2025
Sponsor: University of Cape Town
Overall Status: Active - Not Recruiting

Phase

2

Condition

Cardiovascular Disease

Heart Disease

Cardiac Disease

Treatment

high dose Rifampicin (RIF)

Clinical Study ID

NCT04521803
IMPI-3 DMID 20-0007
  • Ages > 18
  • All Genders

Study Summary

The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10).

This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the treatment of PCTB.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged >18 years

  2. Suspected PCTB with confirmed pericardial effusion on echocardiography (i.e., echofree space of ≥1 cm anterior to the right ventricle in diastole)

  3. Consent to study participation including testing for HIV-1 (if HIV status isunknown)

  4. Microbiologically detected Mtb in PCF or diagnosis of probable PCTB. Probable PCTB (in the absence of a positive pericardial fluid culture) will be defined as perMayosi et al.4:

  5. Evidence of pericarditis with microbiologic confirmation of Mtb- infectionelsewhere in the body and/or

  6. Exudative, lymphocyte predominant effusion with elevated adenosine deaminase (≥35 U/L)

  7. Participant will undergo pericardiocentesis (as per clinical indication)

  8. Within 5 days of ATT initiation

Exclusion

Exclusion Criteria:

  1. Glomerular filtration rate <30ml/min or renal failure requiring dialysis

  2. Rifampin-resistant TB

  3. Severe concurrent opportunistic infection

  4. Contraindication to placement of intra-pericardial catheter

  5. Failed pericardiocentesis procedure and/or failure of placement of intra-pericardialcatheter

  6. Any disease or condition in which the use of the standard anti-TB drugs (or any oftheir components) are contraindicated. This includes, but is not limited to, allergyto any TB drug or their components.

  7. In females: a positive urine pregnancy test result

  8. Confirmed autoimmune disorders (e.g. systemic lupus erythematosus)

Additional Exclusions for Gadolinium contrasted CMR

  1. Any implanted devices that are not MR compatible (e.g. pacemaker, defibrillators,cerebral aneurysm clips, cochlear implants etc.)

  2. Claustrophobia

  3. Gadolinium allergy

  4. Inability to lie on a flat surface for prolonged periods of time (e.g. severecongestive cardiac failure)

  5. Breastfeeding

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: high dose Rifampicin (RIF)
Phase: 2
Study Start date:
January 10, 2022
Estimated Completion Date:
February 28, 2026

Study Description

IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Phase 2b Randomized, placebo-controlled, double-blinded clinical trial

The trial will enroll 100 adult participants with pericardial TB from two research sites in South Africa, with no exclusions being made on the basis of sex/gender, racial or ethnic group.

Consenting participants will be stratified by HIV status and PCF GX-Ultra status, then randomized 1:1 to receive either standard of care anti-tuberculosis treatment (ATT) or standard of care plus high dose Rifampicin (RIF), both administered orally for 2 months, followed by a continuation phase of 4 months' RH at standard doses.

Connect with a study center

  • Nelson Mandela Academic Hospital

    Mthatha, Eastern Cape 5099
    South Africa

    Site Not Available

  • Groote Schuur Hospital

    Cape Town, Western Cape 7925
    South Africa

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.